According to ABC News' latest report, almost 38,000 Americans are diagnosed with HIV (human immunodeficiency virus) every year. There are already treatments to prevent HIV infection. In 2012, the Food ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has ...

An injectable form of PrEP has been given “breakthrough therapy” designation by the FDA. PrEP, or pre-exposure prophylaxis, uses antiretroviral therapies designed to combat HIV to help prevent ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

A study suggests that a new medication – taken as an injection every two months – could be more effective at preventing HIV transmissions than Truvada. Truvada was the first medication approved by the ...

BRISBANE, Australia – When given a choice for pre-exposure prophylaxis (PrEP) to prevent infection with HIV, women preferred injectable cabotegravir (Apretude) every 2 months rather than an oral pill ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...